Your search for severe asthma returned 398 results

A post-hoc analysis of the LAVOLTA I and II trials assessed the effect of lebrikizumab on asthma exacerbations according to patients’ FeNO and eosinophil levels.

The phase 3 SYNAPSE clinical trial evaluated the efficacy of mepolizumab in improving sense of smell in patients with chronic rhinosinusitis with nasal polyps.

An analysis of phase 3 NAVIGATOR trial data assessed the effect of tezepelumab on the percentage of asthma symptomatic days in adults and adolescents.

Study B of the CUPID trial evaluated dupilumab in 83 patients with CSU aged 12 to 80 years who remained symptomatic despite standard of care treatment and were intolerant or incomplete responders to omalizumab.

The sBLA is supported by data from the phase 3 LIBERTY AD PRESCHOOL study.

The FDA has approved a 40mg prefilled syringe for Nucala (mepolizumab) as add-on maintenance treatment for children with severe eosinophilic asthma.

The phase 3 PRIME study evaluated dupilumab in 151 adults with inadequately controlled prurigo nodularis.

Tezspire is a first-in-class human monoclonal antibody that works by blocking thymic stromal lymphopoietin, an epithelial cytokine involved in the initiation and persistence of airway inflammation.

Review the December 2021 notable drug approvals.

Tezspire is a first-in-class human monoclonal antibody that works by blocking thymic stromal lymphopoietin.